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Abstract 
Background: Early and accurate acute kidney injury (AKI) detection may improve patient outcomes and reduce 
health service costs. This study evaluates the diagnostic accuracy and cost‑effectiveness of NephroCheck and NGAL 
(urine and plasma) biomarker tests used alongside standard care, compared with standard care to detect AKI in hospi‑
talised UK adults.
Methods: A 90‑day decision tree and lifetime Markov cohort model predicted costs, quality adjusted life years 
(QALYs) and incremental cost‑effectiveness ratios (ICERs) from a UK NHS perspective. Test accuracy was informed by 
a meta‑analysis of diagnostic accuracy studies. Clinical trial and observational data informed the link between AKI 
and health outcomes, health state probabilities, costs and utilities. Value of information (VOI) analysis informed future 
research priorities.
Results: Under base case assumptions, the biomarker tests were not cost‑effective with ICERs of £105,965 (Nephro‑
Check), £539,041 (NGAL urine BioPorto), £633,846 (NGAL plasma BioPorto) and £725,061 (NGAL urine ARCHITECT) per 
QALY gained compared to standard care. Results were uncertain, due to limited trial data, with probabilities of cost‑
effectiveness at £20,000 per QALY ranging from 0 to 99% and 0 to 56% for NephroCheck and NGAL tests respectively. 
The expected value of perfect information (EVPI) was £66 M, which demonstrated that additional research to resolve 
decision uncertainty is worthwhile.
Conclusions: Current evidence is inadequate to support the cost‑effectiveness of general use of biomarker tests. 
Future research evaluating the clinical and cost‑effectiveness of test guided implementation of protective care 
bundles is necessary. Improving the evidence base around the impact of tests on AKI staging, and of AKI staging on 
clinical outcomes would have the greatest impact on reducing decision uncertainty.
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Background
Acute kidney injury (AKI) incidence among the adult 
general population is estimated at about 150 per 10,000 
per year [1]. Hospitalised patients are at greater risk 
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following cardiac surgery (ranging from 8 to 40%), 
abdominal surgery (13.4%), and major trauma (21 to 24%) 
[2–5].
Early diagnosis and treatment can prevent AKI pro-
gression, which may reduce the risk of chronic kidney 
disease (CKD), and mortality [1, 6–8]. Patients who 
develop AKI in hospital are more likely to require renal 
replacement therapy (RRT) or intensive care unit (ICU) 
admission for kidney organ support and have longer 
length of stay (LOS). Cost implications to health services 
in England may be as high as £483 million per year [6].
In current standard care, AKI detection relies on moni-
toring changes in serum creatinine and urine output [9]. 
However, serum creatinine levels are not a precise indi-
cator, and can take days to rise leading to delays in AKI 
recognition [2]. Novel biomarkers are intended to help 
detect AKI earlier, allowing initiation of prompt treat-
ment with a care bundle to protect the kidneys, thereby 
improving outcomes and reducing healthcare costs. 
However, clinical and cost-effectiveness evidence for dif-
ferent biomarker tests is sparse, especially prior to admis-
sion to critical care [10–13]. This study uses a decision 
model to estimate the cost-effectiveness of four diagnos-
tic biomarkers from a UK National Health Service (NHS) 
perspective. Value of information (VOI) analyses iden-




The modelled population was UK hospitalised adults, at 
risk of AKI, who were having their kidney function moni-
tored. The modelled population was designed to conform 
to the National Institute for Health and Care Excellence 
(NICE) assessment of diagnostic tests for AKI [14]. At 
model entry the cohort had a mean age of 63, and 54.3% 
were female, based on a published study of AKI incidence 
in a UK population [1].
Interventions and comparators
Four biomarker tests were evaluated [14]. The Nephro-
Check test (Astute Medical) measures two biomarkers 
(tissue inhibitor of metalloproteinase 2 [TIMP-2] and 
insulin-like growth factor binding protein 7 [IGFBP-7]) 
in urine to calculate an AKI risk score. The threshold 
used for the NephroCheck test results to assess the risk 
of AKI was 0.3. The ARCHITECT urine NGAL assay 
(Abbott) is a chemiluminescent microparticle immuno-
assay to measure NGAL in human urine. The BioPorto 
NGAL test (BioPorto Diagnostics) is a particle-enhanced 
turbidimetric immunoassay to determine NGAL in 
either human urine or plasma (considered as two differ-
ent tests). No restrictions were placed on the threshold 
for assessing the risk of AKI for the NGAL test results 
(see the Diagnostic accuracy section for more details). 
All tests were assessed in addition to standard clini-
cal monitoring (e.g. serum creatinine and urine output 
monitoring), compared to standard clinical monitoring 
alone. The reference baseline levels of serum creatinine 
are defined according to current clinical criteria (Risk, 
Injury, Failure, Loss of kidney function, and End-stage 
kidney disease (RIFLE), Kidney disease:  Improving 
Global Outcomes (KDIGO) and Acute Kidney Injury 
Network (AKIN)).
Model structure
A decision tree combined with a Markov cohort model 
was developed in TreeAge Pro (TreeAge Software, Wil-
liamstown, MA, 2019). The model structure (Fig.  1) 
was adapted from Hall et  al. [10], who shared access to 
their model files under a ‘creative commons’ licence. The 
model structure was validated with clinical experts in 
nephrology and intensive care medicine.
Decision tree (up to 90 days)
The decision tree described the diagnostic accuracy and 
short-term health outcomes (admission to ICU, need for 
RRT, hospital LOS, and mortality) up to 90 days after test 
initiation. Tests may be true positive (TP), false nega-
tive (FN), true negative (TN) or false positive (FP). Bio-
marker tests may be beneficial if they can promptly and 
accurately identify AKI to enable appropriate early ini-
tiation of a protective care bundle which in turn can pre-
vent further kidney damage. The benefits of prevention 
or a reduction in AKI severity (KDIGO stage) include 
reductions in LOS, need for RRT, ICU admission, devel-
opment of CKD and the risk of mortality. All test posi-
tive patients are modelled to receive the care bundle 
but only those with a TP test result receive early treat-
ment benefits. AKI prevention means keeping patients 
in the “No AKI” model pathway. It is assumed that FN 
tests incur the same risks as standard care, assuming 
that all positive AKI cases will eventually be identified 
using serum creatinine monitoring. Due to a lack of evi-
dence, no negative effects of FP tests were assumed  for 
the base case analysis but we recognise that identifica-
tion and kidney support in AKI may not be risk free 
[15]. Scenario analyses explored an increased mortality 
risk associated with unnecessary removal of nephrotoxic 
treatments.
Markov model (lifetime horizon)
The Markov cohort model described CKD progres-
sion from early to subsequent end-stage renal disease 
(ESRD), need for dialysis, transplant, and mortality over 
a lifetime horizon from day 90 to death. The surviving 
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cohort (at 90 days) enter the Markov model in either 
the “CKD (1-4)” or “No CKD” state. The cohort then 
transition between six health states: “No CKD”, “CKD 
(1-4)”, “ESRD”, “Post ESRD + dialysis”, “Post-transplant” 
and “Death” in annual model cycles, according to a set 
of transition probabilities. A half-cycle correction is 
applied. It was assumed that reversion to milder states 
(e.g. “No CKD”) was not possible. Those that had a failed 
transplant returned to dialysis, after which a subsequent 
transplant was possible. Other than the initial CKD risk, 
health state transitions are independent of 90-day AKI 
status. An annual mortality risk was modelled accord-
ing to disease-specific [16–18] and age, and sex-adjusted 
general population risks [19].
Model parameters
Full details of all model parameters (transition prob-
abilities, relative risks, costs, and utilities) are provided in 
Additional file, Table 1.
Diagnostic accuracy
Test sensitivity and specificity were obtained from a sys-
tematic review and random-effects meta-analysis where 
possible. This model was chosen because of the heteroge-
neity across studies regarding different threshold values 
used for a positive NGAL test and variation in the classi-
fication systems used to determine AKI (KDIGO, RIFLE 
and AKIN). Table 1 describes the pooled diagnostic accu-
racy estimates obtained from 22 studies.
Clinical parameters
AKI incidence and severity were based on KDIGO stag-
ing (peak AKI status during hospitalisation), obtained 
from a 2012 cohort of people admitted acutely to hos-
pital in the Grampian region of Scotland [1].
The impact of early delivery of a KDIGO care bun-
dle on AKI was assumed to be that obtained from 
Meersch et  al., a German trial of 276 NephroCheck 
positive patients, which reported a 16.6% (95% CI: 
5.5 to 27.99%) absolute risk reduction in 72-h AKI for 
patients treated with a KDIGO care bundle compared 
to standard care [20]. The study also provided data to 
enable calculation of the impact of the care bundle on 
AKI severity (KDIGO staging). No comparable data 
were available for NGAL tests. Clinical expert advice 
indicated that NGAL may not detect kidney stress 
before damage occurs. It was therefore conservatively 
assumed that NGAL may reduce severity but could not 
prevent AKI.
The modelled hospital and post-discharge health out-
comes associated with changes in AKI severity (need 
for ICU, 90 day mortality, hospital length of stay) were 
obtained from a re-analysis of published observational 
data from N = 17,630 patients admitted to Grampian 
(Scotland) hospitals in 2003, who were having their 
kidney function monitored through a blood test, and 
assumed to be at high risk of AKI [18, 21, 22]. Those with 
AKI, and those classified as having more severe AKI were 
more likely to need ICU care, had longer hospital LOS, 
Fig. 1 Model structure
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and had a higher 90-day mortality risk. For those with 
AKI, the probability of developing CKD was calculated 
using hazard ratios from a recent systematic review and 
meta-analysis [23].
The modelled effect on outcomes of averting or 
reducing the severity of AKI through testing may be 
confounded with patient underlying characteristics. 
Therefore, based on clinical expert advice, and the pub-
lished literature [20, 23, 24], we assumed that AKI miti-
gation/prevention leads to the full observed impact on 
CKD risk reduction obtained from the Grampian cohort 
data [23], some improvement (half the observed effect) in 
the need for ICU and hospital LOS and no improvement 
(none of the observed effect) in 90-day mortality [20, 
24]. The extent to which observed associations are causal 
remains uncertain. Therefore, the proportion of the effect 
size applied in the model is varied in scenario analyses.
For the Markov cohort model, the proportion starting 
in the CKD state was calculated based on CKD preva-
lence (11.05% from the Grampian dataset) and hospital 
AKI severity. The remaining cohort with no initial CKD 
experienced an ongoing risk of developing CKD in the 
following cycles [10]. The remaining transition probabili-
ties were obtained from a Swedish multi-centre cohort 
study, the SHARP trial, Scottish registry data and the UK 
Renal Registry [17, 25–27].
Costs
NHS perspective costs include the costs of test kits, staff 
time, hospital resource use up to day 90 (this included 
total number of days in hospital ward and ICU from the 
point of index admission up to day 90), hospital resource 
use after day 90 (including longer term hospital costs 
post discharge from hospital ward/ICU) and long term 
costs of CKD over a lifetime horizon.
Biomarker test costs included analysers, equipment, 
maintenance, consumables, staff time and training. Costs 
were based on manufacturer provided data, clinical 
expert opinion and unit costs for staff time (Additional 
file, Table 2). An additional three days of a preventative 
KDIGO care bundle was given to all test positive patients. 
This consisted of the avoidance of nephrotoxic agents, 
discontinuation of certain medications (ACE inhibitors 
and ARBs), regular monitoring of serum creatinine and 
urine output, steering clear of hyperglycaemia, avoiding 
radio contrast and intense hemodynamic monitoring. 
This was costed at £106.36, based on NICE guidelines 
for preventing AKI and included the costs of nephrolo-
gist and pharmacist time, intravenous fluids and clinical 
review of medications including those for blood pressure 
(ACE inhibitors, ARBs) [9]. Costs of LOS on a hospital 
ward, ICU, and RRT delivery were based on NHS refer-
ence costs [28].
Markov health states costs for those without CKD, 
included outpatient follow-up, as an average of those 
who had and had not received ICU care as part of their 
index admission [25]. The remaining health state costs 
were obtained from the SHARP trial, including outpa-
tient, day-case and inpatient admissions [17]. Additional 
medication costs (immunosuppressant for a transplant 
patient, ESA for dialysis patients and blood pressure 
medications for dialysis patients) were obtained from the 
Table 1 Sensitivity and specificity data obtained from the systematic review
MVN Multi-Variable Normal
A Note that some studies evaluated more than one of the candidate tests
TestA Parameter Mean value
(95% CI)
Mean (logit scale) Standard error 
(logit scale)
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literature, NICE guidance and the BNF [16, 29–31]. All 
costs were incorporated in 2017/18 values, and inflated 
where necessary using the Cochrane and Campbell eco-
nomic methods group online tool [32].
Quality adjusted life years (QALYs)
QALYs combine length (accounting for mortality) and 
quality of life into a single measure for use in decision-
making. Utility data were obtained from an updated ver-
sion of the systematic review published by Hall et al. [10]. 
For the acute decision tree phase, no new utility studies 
were identified. Therefore, utilities from Hall et al. were 
used. The review identified several health state utility 
values for the post discharge time period [33], CKD [34], 
ESRD [34] and dialysis [35] states. Where several util-
ity studies were available, we prioritised those that used 
EQ-5D with a UK value set and larger sample sizes. All 
utilities used in the model were age and sex adjusted to 
allow quality of life to reduce naturally over time and to 
reconcile source study characteristics with the character-
istics of the modelled cohort [36, 37].
Analysis
The decision model was analysed probabilistically using 
Monte Carlo simulation, with 1000 random draws. 
Costs and QALYs accruing beyond the first year were 
discounted at 3.5% per annum [38]. Incremental cost-
effectiveness ratios (ICERs) were calculated for each test 
compared to the next best alternative, excluding those 
that were more costly and less effective than an alter-
native (dominated). Uncertainty was illustrated using 
cost-effectiveness acceptability curves (CEACs) and a 
comprehensive range of scenario analyses were carried 
out to explore the impact of key assumptions on the 
ICER. Subgroup analyses were conducted to explore the 
cost-effectiveness by parameterising the model using 
diagnostic accuracy data from several pre-defined sub-
groups (critical care only, post cardiac surgery only) (see 
Additional file, Table 5 and 6).
Expected value of perfect information (EVPI) and the 
expected value of perfect parameter information (EVPPI) 
were calculated for the model comparison of Nephro-
Check vs. standard care using the Sheffield Acceler-
ated Value of Information (SAVI) tool [39, 40]. In this 
case, EVPI helps establish the economic value of future 
research (for example a new randomised trial) that could 
help inform the cost-effectiveness of NephroCheck vs. 
standard care by comparing the decision value under 
current and perfect information. Given a positive EVPI 
indicating that future research is worthwhile, we then 
used EVPPI analysis to identify research areas, specifi-
cally model parameters, where future research should be 
prioritised to have the greatest impact on reducing deci-
sion uncertainty [39]. To complete the EVPI and EVPPI 
calculations the target population size was assumed to be 
the number of AKI episodes in England in 2018 (564,738) 
[26], and the duration of time where the technology is 
relevant was assumed to be 10 years [39].
Results
The base case analysis showed that none of the tests 
achieved an ICER <£20,000 per QALY gained compared 
to standard care (Table  2). Amongst the testing strate-
gies, NephroCheck was the most promising test due to 
its potential ability to avert AKI.
Scenario analyses show that there is substantial resid-
ual uncertainty around the results. Full details of all 
scenario analyses are provided in the Additional file, 
Tables  3 and 4. Results are most sensitive to assump-
tions about the impact of AKI prevention on health 
Table 2 Base case cost‑effectiveness results
Dominated: more costly and less effective; P(C/E): probability that a test is cost-effective at a threshold value of willingness to pay for a QALY of £20,000
Cost Incremental Cost QALY Incremental QALY ICER (incremental) ICER vs. 
standard 
care
p (C/E) @ 20 k p (C/E) @ 20 k 
vs. standard 
care
Base case: Full associative effect of AKI mitigation on a) the risk of CKD within the first year, b) half the associative effect on the need for 
ICU, c) half the associative effect on hospital/ICU LOS, and d) no associative effect on 90-day mortality.
Standard care (Scr) £22,978 – 6.07277 – – – 64.5% –
Test 1 (Nephro‑
Check)
£23,016 £38 6.07313 0.00036 £105,965 £105,965 29.7% 32.0%
Test 3 (NGAL urine ‑ 
BioPorto)
£23,049 Dominated 6.07290 Dominated Dominated £539,041 5.3% 11.0%
Test 2 (NGAL 
plasma ‑ BioPorto)
£23,064 Dominated 6.07290 Dominated Dominated £633,846 0.3% 7.3%
Test 4 (NGAL urine ‑ 
ARCHITECT)
£23,065 Dominated 6.07289 Dominated Dominated £725,061 0.0% 6.3%
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outcomes. The extent to which preventing or reducing 
severity of AKI through early test guided protective 
KDIGO care bundles can truly reduce the risk of ICU 
admission, 90-day mortality, hospital length of stay 
and CKD risk is a major driver of model uncertainty. 
Assuming that the full observed relationship between 
AKI and these outcomes can be achieved through early 
detection and prevention (Scenario 1), NephroCheck 
is the most likely test to be cost-effective (98.5% prob-
ability if society is willing to pay £20,000 for a QALY 
gain). However, assuming none of the benefits in health 
outcomes can be achieved (Scenario 2), means none of 
the tests are cost-effective, demonstrating that it is not 
sufficient to prevent AKI, unless that prevention can 
definitively improve health outcomes.
Several scenario analyses increase the probability 
of NephroCheck being cost-effective (at a threshold 
value of £20,000 per QALY gained): including a daily 
excess AKI cost to patients in hospital ward/ICU over 
and above the hospital ward/ICU daily cost (Scenario 
4, 98.8%), applying long-term costs and mortality risks 
that depend on whether the patient entered ICU or not 
(Scenario 6, 97.2%), assuming a lifetime excess CKD 
risk for AKI patients (Scenario 7, 55.5%), and applying 
a higher AKI prevalence (Scenario 10, 63.1%). On the 
other hand, some scenario analyses reduce the prob-
ability of the NephroCheck test being cost-effective: 
including removing RRT costs (Scenario 5, 27.7%), 
increasing the number of times a test is conducted to 
two (Scenario 11, 9%), and applying an additional mor-
tality risk (RR = 1.5) to all FP test results (Scenario 12; 
0%).
Given that our model base case assumes that NGAL 
cannot avert AKI, the probability of cost-effectiveness 
tends to be lower for the NGAL test strategies than 
NephroCheck across the scenario analyses. However, an 
analysis assuming that NGAL can also avert AKI, results 
in the BioPorto urine NGAL test being the optimal strat-
egy (Scenario 3, 43.5%), though evidence to support the 
validity of this assumption is weak.
Subgroup analyses showed similar cost-effectiveness 
results for the critical care subgroup but low probabili-
ties of cost-effectiveness in the cardiac care subgroup. 
Any suggestion of differences in cost-effectiveness across 
subgroups should be interpreted cautiously due to sparse 
diagnostic accuracy data in each subgroup, and due to 
a lack of subgroup specific data to inform downstream 
costs, utility and event probability parameters.
Value of information analysis
The EVPI was £11.62 per patient and approximately 
£66 million at the population level over a ten-year time 
horizon, indicating that there is substantial value to be 
obtained from future research (such as well-designed 
randomised trials) to investigate the cost-effectiveness 
of NephroCheck vs. standard care (Fig. 2). Among indi-
vidual model parameters, the EVPPI value was highest 
for the impact of early treatment on AKI prevention 
(£5.05 million) and the impact of AKI prevention on 
90-day mortality (£3.66 million), indicating that research 
funding allocated to addressing these research questions 
would have the greatest impact on reducing decision 
uncertainty. The group population EVPPIs were £19.29 
million for baseline probabilities, £8.98 million for costs 
and £0 for the utilities. This indicates there is adequate 
information available on utilities, but more research 
is required on overall AKI disease progression, down-




This economic model compared the cost-effectiveness 
of four biomarkers NephroCheck, ARCHITECT urine 
NGAL and BioPorto urine and plasma NGAL to identify 
AKI in a UK hospital setting. The optimal, most cost-
effective strategy was unclear, driven predominantly by 
the lack of clinical trial evidence of the impact of the bio-
marker tests on direct health outcomes such as ICU need, 
hospital LOS, development of CKD and mortality. Under 
base case assumptions, none of the biomarker tests were 
cost-effective. However, when exploring alternative anal-
yses around uncertain parameters, the NephroCheck test 
had the greatest potential to achieve cost-effectiveness. 
That is because of NephroCheck’ s theoretical ability to 
pre-empt kidney damage and because the only evidence 
available to support an impact of a positive biomarker 
test guided implementation of an AKI care bundle is for 
NephroCheck [20].
The VOI analysis clearly shows that future research 
to resolve this decision uncertainty is worthwhile and 
that future research effort should be prioritised towards 
determining the clinical-effectiveness of novel biomarker 
tests in terms of AKI prevention through early interven-
tion and 90-day mortality risks. Currently, clinical evi-
dence points to some mitigation or aversion of AKI [20]. 
The observed data demonstrate that people with AKI 
(and more severe AKI) have poorer health outcomes than 
those without AKI (and with less severe AKI). However, 
it is not clear if averting AKI, or reducing its severity can 
fully remove the observed increased risk of adverse health 
outcomes associated with it. For example, Meersch et al. 
showed that early test guided application of a protective 
care bundle reduced AKI incidence and severity, but no 
beneficial effect on health outcomes was demonstrated. 
Similarly, an RCT of an early warning electronic alert 
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system for AKI to trigger a renal consultation showed 
no evidence of a mortality benefit [24]. Hence, limited 
direct evidence exists to support an impact of biomarker 
tests on other health outcomes. Several trials are cur-
rently being conducted that are comparing NephroCheck 
guided initiation of a KDIGO care bundle to standard 
care (e.g. BigpAK1 trial, NEPHROCAR trial and a clinical 
trial in sepsis patients) [41]. These studies will report out-
come data on AKI, 90-day mortality, need for RRT, ICU 
LOS, and hospital LOS. The data provided from these 
studies will be a valuable resource from which to inform 
future economic evaluations.
Current literature
Hall et al. [10] also developed an economic model com-
paring different biomarker tests to assess the risk of AKI 
in ICU patients. The results for the biomarker tests in 
this study are less favourable to those reported in Hall 
et  al. for several reasons. Our study scope focused on 
people not in ICU who could be considered for criti-
cal care rather than ICU patients where critical care is 
already being delivered. Therefore, the AKI prevalence is 
lower than in Hall et  al. The higher the prevalence, the 
more likely the tests are to be cost-effective, as shown 
in our scenario analysis. This implies that careful con-
sideration should be given to identifying subsets (e.g. 
post-major surgery) of those in hospital who would be 
most likely to benefit from testing and could be targeted 
in future trials. Furthermore, there were differences in 
test accuracy data between the reviews, with our review 
showing lower sensitivity for NephroCheck. This may be 
because new studies have become available since Hall 
et  al. and the broader setting considered in our model. 
Finally, the approach to the estimation of costs is differ-
ent; our analysis does not include an excess daily AKI 
cost for patients while in hospital, due to concerns about 
double counting costs already captured through AKI 
staging. An additional excess daily cost was added in 
scenario analysis. We also do not differentiate between 
the follow-up costs of ICU and non-ICU patients in 
the longer-term, though we explored this in scenario 
analyses.
Fig. 2 Prioritised areas for future research
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Strengths and limitations
A key strength is that the economic model is built on the 
basis of a comprehensive evidence synthesis to identify 
the diagnostic accuracy of the biomarker tests. The eco-
nomic model was populated using both trial and real-
world clinical registry data ensuring a high degree of 
external validity for the model inputs. The results are pol-
icy relevant and the VOI analysis in particular can help 
guide future research prioritisation and hence help avoid 
future research waste.
Our analysis was limited to the scope of the research 
question. For example, our results are only relevant to 
testing for AKI in a hospital setting. In addition, we rec-
ognise that NephroCheck and NGAL are two biomark-
ers among many. AKI biomarkers differ in what their 
measurement represents, across spectrums of inflamma-
tion, damage, and function loss at different time points. 
It may be that either a panel of biomarkers or sequential 
use of tests would be more clinically useful. However, 
it was not possible to evaluate these uses in our study. 
Additionally, given the broad heterogeneity of AKI 
causes, it is possible that further research will be able 
to delineate specific clinical circumstances or subsets of 
people in which biomarkers have the greatest potential 
to provide a cost-effective use of resources. Although 
our study had no ethnic restriction on inclusion criteria, 
future studies, especially clinical trials, should ensure 
diverse recruitment across ethnic and demographic 
populations. Furthermore, a separate analysis would be 
needed to assess the potential for stepping down care 
among those whose sole requirement for critical care is 
for kidney support.
This model did not account for CKD regression (i.e., 
a subset of people who have improving kidney func-
tion over time) [42] but used the conventional model for 
CKD where the majority are stable and a minority pro-
gress through CKD stages accumulating higher costs and 
worse outcomes, in line with previous kidney disease 
models [10]. It is unclear how this may or should influ-
ence mortality outcomes, or health care resource use. 
Furthermore, our model does not capture regression or 
progression between CKD stages (but applied average 
hospital care costs and utilities for this patient group) 
with a very small chance of progressing to CKD 5. There-
fore, the impact of incorporating regression on cost-
effectiveness findings is uncertain.
The results of the base case analyses should be inter-
preted cautiously because of the heterogeneous nature 
of the diagnostic accuracy studies in terms of NGAL 
threshold levels, timing of the sample collection, time 
of AKI diagnosis, definition of AKI, prevalence of AKI 
and definition of the population. Moreover, the clinical-
effectiveness review identified no direct evidence about 
the incremental benefit of biomarker tests on clini-
cally important and patient relevant health outcomes. 
We had to rely on a linked evidence approach, which 
contributed substantial decision uncertainty regarding 
cost-effectiveness.
Conclusions
Current evidence is inadequate to support the cost-effec-
tiveness of general use of biomarker tests. To minimise 
uncertainty about the cost-effectiveness of biomarker 
tests future research should be prioritised towards high 
quality randomised trials that target select patient sub-
sets and assesses the added value of test guided use of 
AKI care bundles on clinically important and patient rel-
evant health outcomes, in particular 90-day mortality.
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